Naproxen: Difference between revisions

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

@@ Line 27: / Line 27: @@
 ==Background Information==
-Naproxen was first released to the prescription drug market in 1976 under the name Naprosyn.  In 1980 its counterpart salt, naproxen sodium, was released for prescription only under the name Anaprox.  The FDA approved naproxens use for an over-the-counter drug in low doses, advertised as Aleve.
+Naproxen was first released to the prescription drug market in 1976 under the name Naprosyn.  In 1980 its counterpart salt, naproxen sodium, was released for prescription only under the name Anaprox.  The FDA approved naproxens use for an over-the-counter drug in low doses, advertised as Aleve and marketed by Bayer HealthCare.
- The U.S. Food and Drug Administration (FDA) approved its use as an over-the-counter (OTC) drug in 1994, where OTC preparations are mainly marketed by Bayer HealthCare under the trade name Aleve and generic store brand formulations. In Australia, packets of 275 mg tablets of naproxen sodium are Schedule 2 pharmacy medicines, with a maximum daily dose of 5 tablets or 1375 mg. In the UK, 250 mg tablets of naproxen were approved for OTC sale under the brand name Feminax Ultra in 2008, for the treatment of primary dysmenorrhoea in women aged 15 to 50.[1] Aleve became available over-the-counter in most provinces in Canada on 14 July 2009, with the exception of Quebec. It most recently became available in British Columbia in March 2011.
 ==Chemical Properties==